Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

CentryMed’s CMDE005 Bispecific Antibody Receives FDA Clinical Approval for EGFR Positive Tumors

Fineline Cube Apr 28, 2025

Zhejiang-based Zhejiang Shimai Pharmaceutical Co.,Ltd (CentryMed)’s CMDE005, an anti-EGFR×CD3 enzyme-controlled bispecific antibody (BsAb) developed using...

Company Drug

Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy

Fineline Cube Apr 28, 2025

US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...

Company Drug

Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors

Fineline Cube Apr 28, 2025

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...

Company Medical Device

Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China

Fineline Cube Apr 28, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...

Company Medical Device

Sihuan Pharmaceutical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Apr 28, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has secured marketing approval...

Others

Roche’s Q1 2025 Results: Pharma Sales Drive 8% Growth Amidst Flat Diagnostics

Fineline Cube Apr 28, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) reported Q1 2025 financials with global group...

Company

BMS Q1 2025 Results: Opdivo Sales Up 12% Despite Overall Revenue Decline

Fineline Cube Apr 28, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) released its Q1 2025 financial results, showing a...

Company

Merck Q1 2025 Results: Keytruda Sales Grow 6% Despite Gardasil Dip in China

Fineline Cube Apr 27, 2025

Global pharmaceutical company Merck (NYSE: MRK) released its Q1 2025 financial results, showing total sales...

Company Drug

Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors

Fineline Cube Apr 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...

Company Drug

InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for First-line CLL/SLL Treatment

Fineline Cube Apr 27, 2025

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has obtained regulatory approval from...

Company Deals

Chipscreen Biosciences Cuts Private Placement Proceeds to RMB 950 Million

Fineline Cube Apr 27, 2025

Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has revised its private placement proceeds to RMB...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Receives NMPA Approval for Melanoma Treatment

Fineline Cube Apr 27, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received another...

Company Drug

Innovent Biologics’ Aoyixin Wins NMPA Approval for First-line NSCLC Treatment

Fineline Cube Apr 27, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another indication approval from...

Company Drug

CSPC Pharmaceutical Group Gains NMPA Approval for SYH2068 siRNA Clinical Trials

Fineline Cube Apr 27, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has obtained approval from China’s National Medical Products...

Company Deals

Grand Pharma Group and Sirtex Medical US Launch Commercial Partnership in Medical Innovation

Fineline Cube Apr 27, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical...

Company Deals Drug

Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)

Fineline Cube Apr 27, 2025

China-based Shanghai Henlius Biotech Inc., (HKG: 2696) has entered into a licensing agreement with South...

Policy / Regulatory

Digital-Intelligent Transformation of China’s Pharmaceutical Industry: 2025-2030 Plan Unveiled

Fineline Cube Apr 27, 2025

China’s Ministry of Industry and Information Technology, Ministry of Commerce, National Health Commission (NHC), and...

Company Deals

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development

Fineline Cube Apr 27, 2025

China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (SHE: 300181) announced an investment of RMB 20 million...

Company Drug

Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication

Fineline Cube Apr 27, 2025

US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...

Company Deals

LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline

Fineline Cube Apr 27, 2025

Shenzhen-based LTZ Therapeutics has reportedly raised USD 40 million in a Series A+ financing round...

Posts pagination

1 … 125 126 127 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.